AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18598318 — intervention group
Group type: EXPERIMENTAL
Intervention: Avecor oxygenator with Trillium (Medtronic)
Number of subjects: 200
Study 18598318 — intervention group
Group type: COMPARATOR
Intervention: Monolyth oxygenator (Sorin)
Number of subjects: 200
Study 15791697 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 50
Study 15791697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 12527244 — intervention group
Group type: EXPERIMENTAL
Intervention: DonJoy Legend functional brace
Number of subjects: 4
Study 10574653 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT (8:0 + 10:0)
Number of subjects: 18
Study 10574653 — intervention group
Group type: COMPARATOR
Intervention: 12:0
Number of subjects: 18
Study 8531542 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg)
Number of subjects: 12
Study 8531542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1987947 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% MK-927
Number of subjects: 76
Study 1987947 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% MK-927
Number of subjects: 76
Study 1987947 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% MK-927
Number of subjects: 76
Study 1987947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 7051722 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg twice daily
Number of subjects: 10
Study 7051722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30835880 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh RBCs
Number of subjects: 90
Study 30835880 — intervention group
Group type: COMPARATOR
Intervention: Aged RBCs
Number of subjects: 90
Study 30157910 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) alongside chemotherapy
Number of subjects: 0
Study 30157910 — intervention group
Group type: COMPARATOR
Intervention: Placebo alongside chemotherapy
Number of subjects: 0
Study 30157910 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomised open-label arm (ZA or placebo for those who decline chemotherapy)
Number of subjects: 0
Study 27020840 — intervention group
Group type: EXPERIMENTAL
Intervention: PhysioDirect telephone assessment and advice service
Number of subjects: 2252
Study 27020840 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy care
Number of subjects: 2252
Study 25216281 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised Clinical Decision Support (CCDS) for paramedics
Number of subjects: 779
Study 25216281 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 779
Study 25216281 — intervention group
Group type: EXPERIMENTAL
Intervention: CCDS
Number of subjects: 779
Study 23035666 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention
Number of subjects: 0
Study 23035666 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 20423524 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention consisting of print resources and four weekly 30-minute telephone support calls.
Number of subjects: 400
Study 20423524 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving printed nutrition information only.
Number of subjects: 400
Study 17297002 — intervention group
Group type: EXPERIMENTAL
Intervention: Inversion-recovery MR imaging
Number of subjects: 8
Study 17297002 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantia nigra/midbrain area ratio
Number of subjects: 8
Study 17297002 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral/medial pixel-intensity ratio
Number of subjects: 8
Study 16140526 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg subcutaneously)
Number of subjects: 54
Study 16140526 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation without amifostine
Number of subjects: 54
Study 16140526 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation with amifostine
Number of subjects: 54
Study 16140526 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine administration
Number of subjects: 54
Study 14642140 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T(50))
Number of subjects: 28
Study 10430112 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg celecoxib twice a day
Number of subjects: 40
Study 10430112 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg celecoxib twice a day
Number of subjects: 40
Study 10430112 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg naproxen twice a day
Number of subjects: 40
Study 10430112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7555513 — intervention group
Group type: EXPERIMENTAL
Intervention: 50/50 human insulin mixture (0.3 U/kg)
Number of subjects: 20
Study 7555513 — intervention group
Group type: EXPERIMENTAL
Intervention: 70/30 human insulin mixture (0.3 U/kg)
Number of subjects: 20
Study 2188525 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine with 2.5 mg droperidol
Number of subjects: 40
Study 2188525 — intervention group
Group type: COMPARATOR
Intervention: Epidural morphine with placebo
Number of subjects: 40
Study 6457384 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle acupuncture at correct sites according to Chinese medicine
Number of subjects: 120
Study 6457384 — intervention group
Group type: COMPARATOR
Intervention: Placebo needles at the same sites
Number of subjects: 120
Study 6457384 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture needles applied at inconsistent sites
Number of subjects: 120
Study 6457384 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser rays at correct acupuncture sites
Number of subjects: 120
Study 6457384 — intervention group
Group type: EXPERIMENTAL
Intervention: Red light at correct acupuncture sites
Number of subjects: 120
Study 6457384 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed light at correct acupuncture sites
Number of subjects: 120
Study 6457384 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared at correct acupuncture sites
Number of subjects: 120
Study 6457384 — intervention group
Group type: EXPERIMENTAL
Intervention: No radiation at all
Number of subjects: 120
Study 31098977 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT-Intensive Management (PIM)
Number of subjects: 2566
Study 31098977 — intervention group
Group type: COMPARATOR
Intervention: PACT
Number of subjects: 2566
Study 28438476 — intervention group
Group type: EXPERIMENTAL
Intervention: Education of families by tab
Number of subjects: 74
Study 28438476 — intervention group
Group type: COMPARATOR
Intervention: Education of families by routine
Number of subjects: 74
Study 25160713 — intervention group
Group type: EXPERIMENTAL
Intervention: Aberration-correcting IOLs
Number of subjects: 198
Study 25160713 — intervention group
Group type: EXPERIMENTAL
Intervention: Aberration-free IOLs
Number of subjects: 198
Study 25160713 — intervention group
Group type: COMPARATOR
Intervention: Spherical IOLs
Number of subjects: 198
Study 23874850 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill running at 70% VO2max on 0% slope
Number of subjects: 18
Study 23874850 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill running at 70% VO2max on 2% slope
Number of subjects: 18
Study 23874850 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill running at 70% VO2max on 7% slope
Number of subjects: 18
Study 21443330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing task delay (lengthened)
Number of subjects: 0
Study 21443330 — intervention group
Group type: EXPERIMENTAL
Intervention: Filler task delay (lengthened)
Number of subjects: 0
Study 17851459 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated low-glycaemic index (GI) breakfast
Number of subjects: 40
Study 17851459 — intervention group
Group type: COMPARATOR
Intervention: Simulated high-glycaemic index (GI) breakfast
Number of subjects: 40
Study 16306933 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term mild hypothermia (n = 108) for 5±1.3 days
Number of subjects: 215
Study 16306933 — intervention group
Group type: COMPARATOR
Intervention: Short-term mild hypothermia (n = 107) for 2±0.6 days
Number of subjects: 215
Study 16306933 — intervention group
Group type: COMPARATOR
Intervention: Short-term mild hypothermia (n = 107)
Number of subjects: 215
Study 16306933 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term mild hypothermia (n = 108)
Number of subjects: 215
Study 16306933 — intervention group
Group type: COMPARATOR
Intervention: Long-term mild hypothermia vs Short-term mild hypothermia
Number of subjects: 215
Study 14722446 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐mg once‐daily topical regimen of miconazole nitrate mucoadhesive buccal tablet (n = 178)
Number of subjects: 357
Study 14722446 — intervention group
Group type: COMPARATOR
Intervention: 400‐mg once‐daily systemic regimen of ketoconazole (n = 179)
Number of subjects: 357
Study 14722446 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐mg once‐daily topical regimen of miconazole nitrate mucoadhesive buccal tablet
Number of subjects: 357
Study 14722446 — intervention group
Group type: COMPARATOR
Intervention: 400‐mg once‐daily systemic regimen of ketoconazole
Number of subjects: 357
Study 11095468 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol supplementation (TES); n = 10; Estraderm, 50 microg/24 h
Number of subjects: 45
Study 11095468 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL); n = 9
Number of subjects: 45
Study 9200170 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0
Study 9200170 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (control)
Number of subjects: 0
Study 8250719 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone sodium succinate (HCSS) 5 mg hydrocortisone/kg body weight
Number of subjects: 10
Study 8250719 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine (0.004 mg/kg)
Number of subjects: 10
Study 3898836 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with carmustine, cyclophosphamide, and prednisone
Number of subjects: 0
Study 3898836 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with melphalan and prednisone
Number of subjects: 0
Study 28605235 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip strengthening (resistance bands, 3 times a week for 4 weeks)
Number of subjects: 26
Study 26867083 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-guided internet-based cognitive-behavioral treatment (iCBT)
Number of subjects: 124
Study 26867083 — intervention group
Group type: COMPARATOR
Intervention: Moderated online discussion forum (Control)
Number of subjects: 124
Study 25601789 — intervention group
Group type: EXPERIMENTAL
Intervention: Durable-polymer zotarolimus-eluting stent
Number of subjects: 2999
Study 25601789 — intervention group
Group type: COMPARATOR
Intervention: Biodegradable-polymer biolimus-eluting stent
Number of subjects: 2999
Study 23488876 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg alcohol
Number of subjects: 28
Study 23488876 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.57 ml/kg energy drink (ED)
Number of subjects: 28
Study 23488876 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol and ED (AmED)
Number of subjects: 28
Study 23488876 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 28
Study 21774589 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg of elemental calcium with 400 IU vitamin D3
Number of subjects: 36282
Study 21774589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282
Study 19179743 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-Use Therapeutic Food (RUTF)
Number of subjects: 31
Study 19179743 — intervention group
Group type: COMPARATOR
Intervention: Cereal legume-based khichri
Number of subjects: 31
Study 16426291 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutivate cream containing FA
Number of subjects: 24
Study 16426291 — intervention group
Group type: COMPARATOR
Intervention: Betnovate cream not containing FA
Number of subjects: 24
Study 15234130 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline visual acuity, contrast sensitivity, and critical print size measurements
Number of subjects: 1052
Study 15234130 — intervention group
Group type: EXPERIMENTAL
Intervention: Drusen characteristics and focal hyperpigmentation evaluation
Number of subjects: 1052
Study 15234130 — intervention group
Group type: EXPERIMENTAL
Intervention: NEI‐VFQ‐25 scores
Number of subjects: 1052
Study 15234130 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between drusen area and focal hyperpigmentation
Number of subjects: 1052
Study 15234130 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall visual function assessment
Number of subjects: 1052
Study 11246305 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) high-dose treatment (6 g on day 1, 12 g on day 2, 18 g on days 3 and 4)
Number of subjects: 30
Study 11246305 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) high-dose treatment
Number of subjects: 30
Study 11246305 — intervention group
Group type: COMPARATOR
Intervention: Control group (mucolytic basis dosage of NAC 3 x 300 mg/day)
Number of subjects: 30
Study 9038857 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025 mg rhGH/kg once daily
Number of subjects: 14
Study 9038857 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I at 0.015 mg/kg twice daily (low dose)
Number of subjects: 14
Study 9038857 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I at 0.03 mg/kg twice daily (mid dose)
Number of subjects: 14
Study 9038857 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I at 0.06 mg/kg twice daily (high dose)
Number of subjects: 14
Study 9038857 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 14
Study 9038857 — intervention group
Group type: EXPERIMENTAL
Intervention: mid dose rhIGF-I
Number of subjects: 14
Study 9038857 — intervention group
Group type: EXPERIMENTAL
Intervention: high dose rhIGF-I
Number of subjects: 14
Study 7722967 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral and psychophysiological predictors
Number of subjects: 80
Study 2644150 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg t.i.d.)
Number of subjects: 26
Study 2644150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 1138682 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (4%)
Number of subjects: 0
Study 1138682 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (2%, 3%, and 4%)
Number of subjects: 0
Study 1138682 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine with pilocarpine
Number of subjects: 0
Study 1138682 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine borate (4%)
Number of subjects: 0
Study 1138682 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 0
Study 1138682 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine
Number of subjects: 0
Study 30409738 — intervention group
Group type: EXPERIMENTAL
Intervention: 2nd generation Cryoballoon for pulmonary vein isolation (PVI)
Number of subjects: 77
Study 28691645 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (15 minutes)
Number of subjects: 22
Study 28691645 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control (rest)
Number of subjects: 22
Study 25909710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesna (360 mg/m2) co-administered with doxorubicin
Number of subjects: 32
Study 25909710 — intervention group
Group type: COMPARATOR
Intervention: Saline co-administered with doxorubicin
Number of subjects: 32
Study 24781527 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg/day erlotinib or a body weight-adjusted dose with subsequent escalations to 200 mg/day
Number of subjects: 55
Study 22366136 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% chemically modified lignin in diet contaminated with 7.9 mg/kg ZEA
Number of subjects: 4
Study 22366136 — intervention group
Group type: COMPARATOR
Intervention: Uncontaminated control diet
Number of subjects: 4
Study 22366136 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet contaminated with 7.9 mg/kg ZEA
Number of subjects: 4
Study 22366136 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lignin in diet contaminated with 7.9 mg/kg ZEA
Number of subjects: 4
Study 20558423 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ms PRP
Number of subjects: 24
Study 20558423 — intervention group
Group type: COMPARATOR
Intervention: 100 ms PRP
Number of subjects: 24
Study 18453647 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation (MSS) given for 12 weeks, either 1 or 3 sessions per week.
Number of subjects: 0
Study 18453647 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 15696578 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (0.4 mg/kg) administered subcutaneously twice weekly for 6 months
Number of subjects: 12
Study 15696578 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered subcutaneously twice weekly for 6 months
Number of subjects: 12
Study 15696578 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 12
Study 15696578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12576241 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate
Number of subjects: 222
Study 12576241 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 222
Study 10501986 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical miotics (n = 28)
Number of subjects: 52
Study 10501986 — intervention group
Group type: COMPARATOR
Intervention: Without miotics (n = 24)
Number of subjects: 52
Study 9116317 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy intake
Number of subjects: 676
Study 9116317 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fat and various types of fats
Number of subjects: 676
Study 9116317 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intakes of beta carotene or vitamin C
Number of subjects: 676
Study 9116317 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intake of carbohydrates and calcium
Number of subjects: 676
Study 9116317 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher triceps skinfold thickness
Number of subjects: 676
Study 8477278 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrained dieters in a negative mood state
Number of subjects: 80
Study 8477278 — intervention group
Group type: COMPARATOR
Intervention: Nondieters (irrespective of restraint status)
Number of subjects: 80
Study 3555370 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg every 8 hours)
Number of subjects: 109
Study 3555370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 3555370 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (drug levels higher than 150 ng/ml)
Number of subjects: 109
Study 3555370 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (drug levels lower than 150 ng/ml)
Number of subjects: 109
Study 31186155 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Team-Based Learning (TBL) sessions
Number of subjects: 105
Study 31186155 — intervention group
Group type: COMPARATOR
Intervention: Traditional lectures
Number of subjects: 105
Study 29042456 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid monotherapy
Number of subjects: 162
Study 29042456 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 162
Study 29042456 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive combination
Number of subjects: 162
Study 29042456 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive regimens
Number of subjects: 162
Study 26689579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal Biacuplasty (IDB)
Number of subjects: 63
Study 26689579 — intervention group
Group type: COMPARATOR
Intervention: Conventional Medical Management (CMM)
Number of subjects: 63
Study 24935517 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and Propofol (sequential use)
Number of subjects: 135
Study 24935517 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 135
Study 22322988 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere processing enhancement
Number of subjects: 0
Study 22322988 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemisphere processing enhancement
Number of subjects: 0
Study 20552171 — intervention group
Group type: EXPERIMENTAL
Intervention: TFMPP 60 mg
Number of subjects: 30
Study 20552171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18486093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery with appendectomy
Number of subjects: 93
Study 18486093 — intervention group
Group type: COMPARATOR
Intervention: Standard cesarean delivery
Number of subjects: 93
Study 15917266 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Cajanus cajan (Ciklavit) administered twice daily for 6 months
Number of subjects: 100
Study 15917266 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice daily for 6 months
Number of subjects: 100
Study 12692572 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-I (trandolapril or perindopril)
Number of subjects: 27
Study 12692572 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB (losartan or candesartan)
Number of subjects: 27
Study 12692572 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-I
Number of subjects: 27
Study 12692572 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB
Number of subjects: 27
Study 10229991 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based clinical decision support system (CDSS)
Number of subjects: 879
Study 10229991 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CDSS)
Number of subjects: 879
Study 10229991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (CDSS)
Number of subjects: 879
Study 8731235 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg etodolac b.i.d for three days after a 36-hour placebo washout
Number of subjects: 20
Study 8731235 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg indomethacin b.i.d for three days after a 36-hour placebo washout
Number of subjects: 20